Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
17,000
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,022.30 | 13.00 | -0.14% |
| CAC 40 | 8,367.33 | 17.54 | -0.21% |
| DAX 40 | 24,626.89 | 44.33 | -0.18% |
| Dow JONES (US) | 52,182.74 | 306.63 | 0.59% |
| FTSE 100 | 10,484.22 | 23.80 | -0.23% |
| HKSE | 22,752.96 | 273.72 | -1.19% |
| NASDAQ | 25,820.14 | 522.53 | 2.07% |
| Nikkei 225 | 70,497.94 | 1,029.83 | 1.48% |
| NZX 50 Index | 13,638.71 | 93.15 | 0.69% |
| S&P 500 | 7,440.43 | 86.41 | 1.18% |
| S&P/ASX 200 | 8,818.80 | 12.70 | -0.14% |
| SSE Composite Index | 4,082.13 | 8.23 | 0.20% |